-- Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has received the establishment inspection report and approval letter from the US Food and Drug Administration for its oncology injectable manufacturing site in Ahmedabad, India.
The US FDA conducted a pre-approval inspection at the facility in November 2025 in relation to the new isolator injectable line, according to a Thursday filing to the Indian stock exchanges.